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Insulin-loaded microemulsions for transdermal delivery were developed using isopropyl myristate or oleic acid as the oil phase,
Tween 80 as the surfactant, and isopropyl alcohol as the cosurfactant. The pseudoternary phase diagrams were constructed to
determine the composition of microemulsions. The insulin permeation ﬂux of microemulsions containing oleic acid as oil phase
through excised mouse skin and goat skin was comparatively greater than that of microemulsions containing isopropyl myristate
asoilphase.Theinsulin-loadedmicroemulsioncontaining10%oleicacid,38%aqueousphase,and50%surfactantphasewith2%
dimethyl sulfoxide (DMSO) as permeation enhancer showed maximum permeation ﬂux (4.93 ± 0.12μg/cm2/hour) through goat
skin. The in vitro insulin permeation from these microemulsions was found to follow the Korsmeyer-Peppas model (R2 = 0.923 to
0.973) over a period of 24 hours with non-Fickian, “anomalous” mechanism. Together these preliminary data indicate the promise
of microemulsions for transdermal delivery of insulin.
1.Introduction
Microemulsion is deﬁned as a dispersed system consisting
of oil, surfactant, cosurfactant, and an aqueous phase at
appropriate ratios [1]. It is a thermodynamically stable
optically transparent isotropic liquid solution with a droplet
diameter usually less than 100nm [2]. Unlike coarse emul-
sions micronized with external energy microemulsions are
based on low interfacial tension. This is achieved by adding
a cosurfactant, which leads to spontaneous formation of
a thermodynamically stable microemulsion. Several inter-
esting characteristics of microemulsions, namely, enhanced
drug solubilization, good thermodynamic stability, ease of
preparation, low viscosity, high drug loading capacity, and
small droplet size, have drawn attention for their use as
v e h i c l e sf o rd r u gd e l i v e r y[ 3–5]. Although microemulsions
can be used to deliver drugs via several routes, these versatile
systems have been extensively studied as vehicles for trans-
dermal administration and have attracted much attention
in recent years [1, 4, 6–9]. As vehicle for transdermal
systems, microemulsions can increase the local or systemic
delivery of drugs by diﬀerent mechanisms [3]. First, their
composition and structure enable them to incorporate a
greater amount of drug than other conventional topical
formulations such as ointments, creams, gels, and lotions.
Second, the diﬀusional barrier of the skin may be modiﬁed
depending on the composition of the microemulsion. Third,
an increased thermodynamic activity of the drug may favour
its partitioning into the skin.
The ﬁrst protein used to treat disease was insulin that
revolutionized the diabetic treatment [10, 11]. Insulin was
widely used clinically for the treatment of insulin-dependent
d i a b e t e sm e l l i t u s( I D D M )o rt y p e - Id i a b e t e s[ 12]. Insulin
is a peptide hormone composed of 51 amino acid residues
and has molecular weight about 5.7kDa [13]. The molecular
structure of insulin is composed of 2 peptide chains: A
chain (21 amino acid residues) and B chain (30 amino acid
residues) [14]. Conventional insulin treatment is basically a
replacement therapy, in which exogenous insulin is admin-
istered subcutaneously to mimic, as closely as possible, the
insulin secretion of the healthy pancreas. The subcutaneous
route has been the mainstay of insulin delivery until now.2 ISRN Pharmaceutics
Althoughparenteralinsulinissatisfactoryintermsofeﬃcacy
in the great majority of cases, this is associated with some
serious adverse eﬀects like peripheral hyperinsulinemia, the
stimulation of smooth muscle cell proliferation, and the
incorporation of glucose into the lipid of arterial walls,
and they might therefore be the causative factor in diabetic
micro- and macroangiopathy [15]. In addition, the burden
of daily injections, physiological stress, pain, inconvenience,
cost, infection, inability to handle insulin, and the localized
deposition of insulin leads to a local hypertrophy and fat
deposition in the injection sites [14, 16]. To limit these
shortcomings,thedeliveryofinsulinbynonparenteralroutes
has gained signiﬁcant attention over the last 2 decades.
Among them, transdermal route for insulin delivery as
an alternative nonparenteral route of administration oﬀers
the advantage in terms of patient compliance and can be
used to treat diabetic patients. During the last few years,
various experimental methodologies have been successfully
developed for facilitating transdermal delivery of insulin
[15, 17–22].
In this present investigation, the transdermal delivery
system of insulin through microemulsions was investigated.
Insulin-loaded microemulsions for transdermal delivery,
containing isopropyl myristate or oleic acid as the oil phase,
Tween 80 as the surfactant, isopropyl alcohol as the cosur-
factant, were prepared. We have selected these components
for the formulation of insulin-loaded microemulsions due
to their skin permeation capacity [1]. The objective of the
presentstudyistoproduceasafeandpainlessinsulindelivery
system and determine the permeation ﬂux of diﬀerent
microemulsion formulations through the skin. We also have
studied the transdermal permeation of insulin from the best
formulations with adding 2% dimethyl sulfoxide (DMSO)
as an additional permeation enhancer for further insulin
permeation improvement.
2.MaterialsandMethods
2.1. Materials. Human insulin, 40IU/mL (Torrent Phar-
maceutical Ltd., India), oleic acid (Fine Chemicals Ltd.,
India), isopropyl alcohol (Qualigens Fine Chemicals, India),
isopropyl myristate (Loba Chemie Pvt. Ltd., India), Tween
80, and dimethyl sulfoxide (Merck Specialties Pvt. Ltd.,
India) were used. All chemicals and reagents used were of
analytical grade.
2.2. Construction of Pseudoternary Phase Diagram.
Microemulsions were prepared by using conventional
titration method. The oil (isopropyl myristate or oleic
acid) and aqueous phases were ﬁrst combined with the
surfactant (Tween 80). Cosurfactant (isopropyl alcohol) was
added gradually with magnetic stirring at room temperature
until the system was transparent. Transparent, single-phase
formulations were indicative of stable microemulsions.
Microemulsions were allowed to equilibrate with gentle
magnetic stirring for 15 minutes.
These microemulsions were then titrated with water
using a micropipette at room temperature. Then, these were
stirred vigorously for a suﬃcient length of time and end
point (onset of turbidity or phase separation) was visually
monitored against a dark background by illuminating the
samples with a white light. The experiments were performed
in triplicate to check reproducibility. From the end point
composition of titrated samples, the mass percent compo-
sition of the components like oil, surfactant, and water was
calculated and plotted on triangular coordinates to construct
pseudoternary phase diagrams [23]. From the microemul-
sion regions in the pseudoternary phase diagram, the three
diﬀerent formulas for the development microemulsions
were selected and prepared. The compositions of selected
microemulsions are shown in Table 1.
2.3. Preparation of Insulin-Loaded Microemulsions. Insulin-
loaded microemulsions were prepared by dissolving insulin
in water (1.4mg/mL, i.e., 40IU/mL) and poured dropwise to
oil (isopropyl myristate or oleic acid) and surfactant (Tween
80)/cosurfactant (Isopropyl alcohol) mixture with vigorous
stirring at room temperature using composition of selected
formulas (Table 1) until the transparent microemulsions
were produced. These insulin-loaded microemulsions were
allowed to equilibrate with gentle magnetic stirring for
15 minutes. Then various formulated microemulsions were
passed through Whatman ﬁlter paper (no. 40).
2.4. Droplet Size and Zeta Potential Determination. At ﬁrst,
the microemulsion 0.1mL was diluted to 10mL of doubled
distilled water, and then droplet size and zeta potential
were determined by a laser scattering particle size analyzer
(MALVERN ZETASIZER, MAL500999).
2.5. Stability of Microemulsions. Physical stabilities of
microemulsions were evaluated by centrifugation (Research
centrifuge, Remi Instruments, India) at 1250rpm for a
period of 5 hours and then examined for any phase
separation [24].
2.6. Preparation of Skin for In Vitro Skin Permeation Study
2.6.1. Mouse Skin. Swiss albino mice weighing 80–100gm
were selected for preliminary permeation study, and the
study was conducted with the approval of Institutional
Animal Ethical Committee. The mice were sacriﬁced using
anesthetic ether. Then the hair from their abdominal region
wasremovedusingananimalhairclipper,and,subsequently,
full thickness of the skin was harvested. The fatty layer,
adhering to the dermis side, was removed by surgical scalpel.
2.6.2. Goat Skin. Selected formulations were further studied
for skin permeation using goat ear skin, obtained from the
slaughter house after sacriﬁcing the animal within 1 hour.
Then the hair was removed from the upper portion of skin
surface using an animal hair clipper, and, subsequently, full
thickness of the skin was harvested. The fatty layer, adhering
to the dermis side, was removed by surgical scalpel.
Finally, these excised skins were thoroughly rinsed with
distilled water and packed in aluminum foils. The skin
samples were stored at −20◦C and used within a week.ISRN Pharmaceutics 3
Table 1: Compositions of insulin-loaded microemulsions and permeation ﬂuxes (μg/cm2/hour) through excised mouse and goat skin.
Formulation no. Oil phase Surfactant and cosurfactant (3:1) Water DMSO Permeation ﬂuxes (μg/cm2/hour)†
Isopropyl myristate Oleic acid (Tween 80 and isopropyl alcohol) Mouse skin Goat skin
F1 40% — 50% 10% — 1.19 ± 0.04 ND∗
F2 35% — 55% 10% — 2.14 ± 0.06 ND∗
F3 30% — 60% 10% — 2.45 ± 0.05 1.64 ± 0.04
F4 — 20% 40% 40% — 4.48 ± 0.09 ND∗
F5 — 15% 45% 40% — 4.65 ± 0.12 ND∗
F6 — 10% 50% 40% — 5.09 ± 0.07 4.47 ± 0.09
F7 30% — 60% 08% 2% ND∗ 1.91 ± 0.05
F8 — 10% 50% 38% 2% ND∗ 4.93 ± 0.12
ND∗: Not determined.
†Mean ± Standard Error, n = 3.
Table 2: Results of curve ﬁtting of the in vitro skin permeation data of various insulin-loaded microemulsions.
Formulation codes R2 values Diﬀusional exponent (n)
Zero order First order Higuchi Korsmeyer-Peppas
F1 0.926 0.591 0.886 0.973 0.426
F2 0.888 0.551 0.914 0.966 0.535
F3 0.802 0.511 0.921 0.963 0.652
F4 0.992 0.598 0.752 0.954 0.833
F5 0.993 0.595 0.741 0.961 0.841
F6 0.989 0.580 0.740 0.923 0.912
2.7. In Vitro Skin Permeation Study by Franz Diﬀusion Cell.
In vitro skin permeation studies were carried out using
Franz diﬀusion cell. The cell consists of two chambers, the
donor and the receptor compartment with a diﬀusion area
of 1.43cm2. The donor compartment was open at the top
and was exposed to atmosphere. The excised mouse skin
was mounted between the compartments of the diﬀusion
cell with stratum corneum facing the donor compartment
and clamped into position. Magnetic stirrer bars were
added to the receptor chambers and ﬁlled with the receptor
phase. Phosphate buﬀer saline (PBS), pH 7.4, was used as
receptor medium. The small concentration of sodium azide
(0.0025%w/v) was added to prevent any microbial growth
[25]. The entire setup was placed over magnetic stirrer, and
the temperature was maintained at 37 ± 0.5◦C. The skin
sections were initially left in the Franz cells for 2 hours in
order to facilitate hydration of the skin samples. After this
period,5mloftheappropriateformulationwasappliedonto
the surface of the skin. 1mL of medium was collected from
receptor compartment at predetermined intervals over study
period and replaced with the same amount of fresh buﬀer.
The amount of permeated drug was measured using UV-
Visible spectrophotometer (Thermo Spectronic UV-1, USA)
by measuring absorbance at λMax 214nm.
2.8. Permeation Data Analysis
2.8.1. Kinetics. The data of in vitro insulin permeation
from various insulin-loaded microemulsions were evaluated
kinetically using various mathematical models like zero-
order, ﬁrst-order, Higuchi, and Korsmeyer-Peppas model
equations.
Zero-order kinetics: F = Kot,w h e r eF represents the
fraction of drug released in time t and Ko is the zero-
order release constant.
First-order kinetics: ln(1 − F) =− K1t,w h e r eF
represents the fraction of drug released in time t and
K1 is the ﬁrst-order release constant.
Higuchi model: F = KHt1/2,w h e r eF represents the
fraction of drug released in time t and KH is the
Higuchi dissolution constant.
Korsmeyer-Peppas model: F = Kptn,w h e r eF
represents the fraction of drug released in time t and
Kp istheKorsmeyer-Peppasreleaserateconstant,and
n is the diﬀusion exponent.
2.8.2. Permeation Flux. The amount of insulin from various
insulin-loadedmicroemulsionswaspermeatedthroughmice
and goat skins were plotted against the function of time.
The slope and intercept of the linear portion of plots were
derived by regression. The permeation ﬂux was calculated as
the slope divided by the skin surface area [26–28]:
Jss = (dQ/dt)ss · 1/A,w h e r eJss is the steady-state
permeation ﬂux (μg/cm2/hour), A is the area of skin tissue
(cm2) through which drug permeation takes place, and
(dQ/dt)ss is the amount of drug passing through the skin per
unit time at a steady state (μg/hour).4 ISRN Pharmaceutics
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Figure 1: Pseudoternary phase diagrams of (a) oil (isopropyl
myristate), surfactant (Tween 80/isopropyl alcohol, in 3:1 ratio),
and aqueous phases and of (b) oil (oleic acid), surfactant (Tween
80/isopropyl alcohol, in 3:1 ratio) and aqueous phases. The shaded
area signiﬁes the microemulsion zone.
3. Results andDiscussion
3.1. Pseudoternary Phase Diagrams. The pseudoternary
phase diagrams of the investigated systems were constructed
to determine the composition of an aqueous phase, an oil
phase containing isopropyl myristate or oleic acid, and a
surfactant/cosurfactant (3:1) phase containing Tween 80
as surfactant and isopropyl alcohol as cosurfactant for the
formulation of microemulsions (transparent solutions) at
room temperature, which were represented in Figures 1(a)
and 1(b), as shaded area. From the microemulsion regions
in the pseudoternary phase diagrams, six formulas were
selected for the development of microemulsions (Table 1,F 1
to F6). Using the composition of selected formulas, insulin-
loaded microemulsions were formulated and investigated.
3.2. In Vitro Skin Permeation. These insulin-loaded
microemulsions were studied for in vitro skin permeation
through excised mouse skin. The amount of insulin
permeated through excised mouse skin over 24-hour period
was plotted against the function of time (Figure 2), and this
result showed higher permeation proﬁle for microemulsion
F6 than others over 24 hours. The permeation ﬂuxes
(μg/cm2/hour) for all these microemulsions through the
mouse skin were determined. The determined permeation
ﬂuxes are given in Table 1. Among all formulations, the
highest permeation ﬂux of 5.09 ± 0.07 μg/cm2/hour was
observed in case of formulation F6, which contained
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Figure 2: In vitro insulin permeation proﬁle through mouse
skin per unit area from insulin-loaded microemulsions (mean ±
standard error, n = 3).
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Figure 3: In vitro insulin permeation proﬁle through goat skin per
unit area from selected insulin-loaded microemulsions (F3 and F6)
without and with 2% DMSO as permeation enhancer (F7 and F8).
(mean ± standard error, n = 3).
lower amount of oleic acid (10%) and considerably higher
amount of aqueous phase (40%) and surfactant phase
(50%). Among microemulsions formulated using isopropyl
myristate as oil phase, the higher permeation ﬂux of 2.45
± 0.05μg/cm2/hour) was observed in case of formulation
F3, which contained lower amount of isopropyl myristate
(30%) and considerably lower amount of aqueous phase
(10%) and surfactant phase (60%). The permeation ﬂux
of microemulsions containing oleic acid as oil phase
was comparatively greater than that of microemulsions
containing isopropyl myristate as oil phase. It is also clear
that the insulin permeation was increased with the increase
in the amount of surfactant phase and aqueous phase in
their composition. This is attributed to skin permeation
enhancement capacity by the surfactants. Surfactants can
loosen or ﬂuidize the lipid matrix of the stratum corneum—
the principal diﬀusional barrier of the skin—and act as skin
permeation enhancer [6]. Also, other components such as
isopropyl myristate or oleic acid, which were used as oil
phase in these formulated microemulsions, serve as skin
permeation enhancers.ISRN Pharmaceutics 5
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Figure 4: The droplet size distribution curves of the selected
insulin-loaded microemulsions: (a) F3 and (b) F6.
In order to predict and correlate the in vitro insulin
permeation behavior from these insulin-loaded microemul-
sions through excised mouse skin, it is necessary to ﬁt
into a suitable mathematical model. The in vitro insulin
permeation data from microemulsions containing insulin
through excised mouse skin were evaluated kinetically by
various mathematical models like zero-order, ﬁrst-order,
Higuchi, and Korsmeyer-Peppas model. The results of the
curve ﬁtting into these above-mentioned mathematical
models indicate the in vitro insulin permeation behavior of
insulin-loaded microemulsions (F1 to F6) (Table 2). When
respective correlation coeﬃcients were compared, F1, F2,
and F3 followed the Korsmeyer-Peppas model (R2 = 0.963
to 0.973), whereas F3, F5, and F6 followed the zero-order
release (R2 = 0.989 to 0.992) over a period of 24 hours.
Again, the Korsmeyer-Peppas model was employed in
the in vitro insulin permeation behavior analysis of these
formulations to ﬁnd out permeation mechanisms: Fickian
(nonsteady) diﬀusional release when n ≤ 0.5, case-II
transport (zero-order) when n ≥ 1, and non-Fickian,
“anomalous” release when the value of n is in between 0.5
and 1 [29]. The determined values of diﬀusion exponent (n)
rangedbetween0.526and0.912(Table 2),indicatingthatthe
drug permeation from these insulin-loaded microemulsions
followed the non-Fickian, “anomalous” mechanism.
From the above results, formulation F3 (isopropyl
myristate as the oil phase) and F6 (oleic acid as the oil
phase) were selected for further study based on their higher
permeation ﬂuxes through the excised mouse skin than their
respective microemulsions. These selected microemulsions
were evaluated for further in vitro skin permeation using
goat ear skin as higher animal skin, and the result showed
higher permeation proﬁle of microemulsion F6 than that
of F3 over 24 hours. The determined permeation ﬂux of
F6 microemulsion (4.47 ± 0.09μg/cm2/hour) through goat
skin was also higher than that of F3 microemulsion (1.64
± 0.04μg/cm2/hour) (Table 1). This result coincided well
with in vitro permeation ﬂux data using mouse skin. The
most likely mechanism for diﬀerent permeation proﬁles for
these two microemulsions may be due to directly insulin
permeation from the droplets of microemulsions to the
stratum corneum without microemulsion fusion to the
stratum corneum and subsequent permeation enhancement.
3.3. Eﬀect of DMSO as Skin Permeation Enhancer on Insulin-
Loaded Microemulsions. We also investigated in vitro skin
permeation of selected microemulsions (F3 and F6) contain-
ing insulin through goat skin using 2% dimethyl sulfoxide
(DMSO) as an additional permeation enhancer for further
improvement of insulin permeation. We also found higher
in vitro p e r m e a t i o nﬂ u x e si nc a s eo fm i c r o e m u l s i o n sw i t h
permeation enhancer (2% DMSO) than those in case of
microemulsions without permeation enhancer (Table 1). It
was also observed that the microemulsion (F7) containing
10% oleic acid, 40% aqueous phase, and 50% surfactant
phase with 2% DMSO as permeation enhancer showed max-
imum permeation ﬂux (4.93 ± 0.12μg/cm2/hour) compared
to the microemulsion containing 30% isopropyl myristate,
10% aqueous phase, and 60% surfactant phase with 2%
DMSO (1.91 ± 0.05μg/cm2/hour). The comparative in
vitro permeation of insulin from the selected insulin-loaded
microemulsions with (F7 and F8) and without (F3 and F6)
2% DMSO as the permeation enhancer through goat skin is
presented in Figure 3.
Permeation enhancers are the substances that facilitate
the absorption of penetrant through the skin by temporarily
diminishing the impermeability of the skin. They may
act by one or more of the three main mechanisms to
increase the skin permeability [26, 28, 30]: (i) improved
partition of the drug or solvent into stratum corneum, (ii)
disruption of highly ordered structure of stratum corneum
lipid, and (iii) interaction with intracellular proteins. In the
presentinvestigation,wehaveused2%DMSOaspermeation
enhancer. DMSO is one of the earliest and most widely stud-
ied penetration enhancers [30]. As permeation enhancer,
DMSO may be operating via both mechanisms, that is,
reducing the skin’s resistance and aiding drug partitioning.
DMSO is strongly hygroscopic and increases the hydration
of the tissue [31]. It also interacts with stratum corneum
protein [32], thereby, increasing the permeability of insulin
through the skin. DMSO can increase the ﬂux by reducing
the resistance of both intercellular and transcellular routes.
Another possible mechanism for ﬂux enhancement may be
due to delamination of horny layer by stress resulting from
cross-currents of highly water interactive DMSO and water
[33]. DMSO is also shown to remove substantial amounts
of polar lipids at physiological temperature and this lipid
extraction may be a mechanism operative in reducing the
barrier function of the skin [34].
3.4.DropletSizeandZetaPotential. Theaveragedropletsizes
and zeta potentials of the above selected two formulations
(F3 and F6) were determined by a laser scattering particle6 ISRN Pharmaceutics
size analyzer (MALVERN ZETASIZER, MAL500999). The
average droplet sizes of F3 and F6 microemulsions were
1.0245μm and 0.415μm, respectively. The droplet size dis-
tribution curves of these two insulin-loaded microemulsions
were presented in Figures 4(a) and 4(b). Due to the small
droplet size of F6 microemulsion, its surface areas are
assumed to be high. Therefore, droplets of microemulsion
settled down to close contact with the skin providing high
concentration gradient and improved insulin permeation
from formulation F6 (containing lower amount of 10% oleic
acid, 40% aqueous phase, and 50% surfactant phase).
Zeta potentials of F3 and F6 microemulsions were
−33.10mV and −19.40mV, respectively. The skin has also
slight negative charge. So, the negative zeta potentials of
these microemulsions containing insulin might cause little
inﬂuence in improved drug permeation through skin due to
electrostatic repulsion between the same charge of the skin
surface and the microemulsion.
3.5. Stability of Microemulsions. All these insulin-loaded
microemulsions were subjected to stability evaluation by
centrifugation method. After 5 hours of centrifugation at
1250rpm, these microemulsions were found to be stable as
there was no sign of phase separation.
4. Conclusion
The major problems of conventional insulin therapies pos-
sess several drawbacks like lower stability to diﬀerent pH and
enzymatic system. For large molecular peptides like insulin,
it is very diﬃcult to improve the permeation eﬃciency
through skin after its transdermal administration. But, the
microemulsion-based transdermal drug delivery systems
may be a better alternative for the conventional insulin
therapy. The insulin-loaded microemulsion containing 10%
oleic acid, 38% aqueous phase, and 50% surfactant phase
with 2% DMSO as permeation enhancer showed maximum
permeation ﬂux and can be transdermally administered in
the treatment of insulin-dependent diabetes mellitus with
improved patient compliance. This study highlighted the
eﬃcacy of insulin-loaded microemulsions for enhanced in
vitro transdermal permeation through both excised mouse
skinandgoatskinandsuggestedtheneedforfurtherdetailed
in vivo investigations.
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